The Academy of Managed Care Pharmacy (AMCP) dossier format was introduced in 2000. The dossier format guides manufacturers in presenting evidence for new pharmaceuticals, biologics, and vaccines to gain reimbursement and/or formulary placement in the United States (US) health care system. Limited information has been published on the role of these dossiers in health care decision making. To characterize decision makers’ use of AMCP dossiers in granting reimbursement and formulary placement for new health technologies, we reviewed the published literature and third-party websites to identify how health care decision makers employ AMCP dossiers. We then developed a discussion guide for use in one-on-one interviews. Participants included 7 medical directors and 3 pharmacy directors who were voting members or chairs of Pharmacy and Therapeutics (P&T) committees at a range of US health plans (national, regional, integrated) (Table 1). Interviews focused on how AMCP dossiers inform decision making and the usefulness of each dossier section. US payers were asked to rate the usefulness of each section of the AMCP dossier on a scale of 0 to 10, where 0 is not useful at all and 10 is extremely useful. US payers were then asked specific questions about each section of the AMCP dossier.
